Aoxin Q&M's acquisition will raise its exposure to PCR testing demand: Deputy CEO
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
AOXIN Q&M Dental Group is boosting its exposure in the Covid-19 testing space. The Catalist-listed company expects its acquisition of a stake in medical technology company Acumen Diagnostics to improve its top and bottom lines.
The deal is a "very good opportunity" for the company to expand its reach into the medtech business, which has been on a tear since the start of the Covid-19 pandemic, Aoxin Q&M's deputy chief executive Ryan San told The Business Times on Tuesday.
Shareholders can expect stronger financials as soon as the second half of 2021 ending December, and higher dividend payouts, he added.
Decoding Asia newsletter: your guide to navigating Asia in a new global order. Sign up here to get Decoding Asia newsletter. Delivered to your inbox. Free.
Copyright SPH Media. All rights reserved.
TRENDING NOW
Vietnam formalises new state leadership, redefining ‘four pillars’ power balance
‘Largest Singapore commercial S-Reit proxy’: analysts say buy CICT shares after Paragon acquisition
From 1MDB to ‘corporate mafia’: Is Malaysia facing a new governance test?
Why where you park your joint venture matters: Lessons from a US$689 million shareholder dispute
